![](https://library.celltelligence.com/wp-content/uploads/2020/05/Allogene-Earnings.png)
$0
Allogene Plans to Expand ALLO-501A’s Pivotal Trial to Europe; Clinical Updates Ahead of ASH 2022; New Manufacturing Facility in China; Allogene’s Q3 2022 Earnings Call Summary
On Wednesday, November 2, Allogene held its Q3 2022 earnings call (press release) highlighting the initiation of ALLO-501A’s (allogeneic CD19 CAR-T) Ph2 ALPHA2 trial in r/r LBCL and its potential expansion into the EU. Furthermore, management announced an R&D showcase on November 29, 2022, to provide updates on the ALLO-501A and ALLO-715 (allogeneic BCMA CAR-T) programs, while results from ALLO-715’s Ph1 UNIVERSAL study will also be presented at ASH 2022. Below, Celltelligence provides insights on Allogene’s potential involvement in ALLO-501A’s ex-US development, while discussing its allogeneic BCMA CAR-T strategy.